Screener
4D Molecular Therapeutics FDMT Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 76,667 | 53,635 |
| Loss from operations | (73,620) | (53,621) |
| Other income (expense): | ||
| Interest income | 4,864 | 5,582 |
| Other income (expense), net | (4) | 67 |
| Total other income, net | 4,860 | 5,649 |
| Net loss | $(68,760) | $(47,972) |
| Net loss per share, basic and diluted | $(1.01) | $(0.86) |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's interest income?
- 4D Molecular Therapeutics (FDMT) reported interest income of $4.86M in Q1 2026.
- How has 4D Molecular Therapeutics's interest income changed year-over-year?
- 4D Molecular Therapeutics's interest income decreased by 12.9% year-over-year, from $5.58M to $4.86M.
- What is the long-term trend for 4D Molecular Therapeutics's interest income?
- Over 3 years (2022 to 2025), 4D Molecular Therapeutics's interest income has grown at a 96.3% compound annual growth rate (CAGR), from $2.57M to $19.48M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about 4D Molecular Therapeutics's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude